WO2011022357A3 - Enzymes de clivage de snare à action rapide - Google Patents

Enzymes de clivage de snare à action rapide Download PDF

Info

Publication number
WO2011022357A3
WO2011022357A3 PCT/US2010/045701 US2010045701W WO2011022357A3 WO 2011022357 A3 WO2011022357 A3 WO 2011022357A3 US 2010045701 W US2010045701 W US 2010045701W WO 2011022357 A3 WO2011022357 A3 WO 2011022357A3
Authority
WO
WIPO (PCT)
Prior art keywords
snare
fast acting
cleaving enzymes
cleaving
enzymes
Prior art date
Application number
PCT/US2010/045701
Other languages
English (en)
Other versions
WO2011022357A2 (fr
Inventor
Paul L. Fletcher
Maryann D. Fletcher
Brian M. Martin
Original Assignee
East Carolina University
The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by East Carolina University, The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services filed Critical East Carolina University
Priority to EP10810460.5A priority Critical patent/EP2467477B1/fr
Priority to US13/390,674 priority patent/US9149666B2/en
Priority to CA2770185A priority patent/CA2770185C/fr
Publication of WO2011022357A2 publication Critical patent/WO2011022357A2/fr
Publication of WO2011022357A3 publication Critical patent/WO2011022357A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/606—Nucleosides; Nucleotides; Nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
    • C12N9/6405—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals not being snakes
    • C12N9/6416—Metalloendopeptidases (3.4.24)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

La présente invention porte sur des enzymes métalloprotéases isolées du venin de scorpion, sur leur acide nucléique et sur leurs séquences d'acide aminé, et sur des procédés d'utilisation de ceux-ci dans le traitement de diverses maladies, divers troubles et divers états cosmétiques.
PCT/US2010/045701 2009-08-17 2010-08-17 Enzymes de clivage de snare à action rapide WO2011022357A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP10810460.5A EP2467477B1 (fr) 2009-08-17 2010-08-17 Enzymes de clivage de snare à action rapide
US13/390,674 US9149666B2 (en) 2009-08-17 2010-08-17 Fast acting SNARE-cleaving enzymes
CA2770185A CA2770185C (fr) 2009-08-17 2010-08-17 Enzymes de clivage de snare a action rapide

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23442909P 2009-08-17 2009-08-17
US61/234,429 2009-08-17

Publications (2)

Publication Number Publication Date
WO2011022357A2 WO2011022357A2 (fr) 2011-02-24
WO2011022357A3 true WO2011022357A3 (fr) 2011-06-16

Family

ID=43607546

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/045701 WO2011022357A2 (fr) 2009-08-17 2010-08-17 Enzymes de clivage de snare à action rapide

Country Status (4)

Country Link
US (1) US9149666B2 (fr)
EP (1) EP2467477B1 (fr)
CA (1) CA2770185C (fr)
WO (1) WO2011022357A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201108108D0 (en) 2011-05-16 2011-06-29 Syntaxin Ltd Therapeutic fusion proteins
GB201219024D0 (en) 2012-10-23 2012-12-05 Syntaxin Ltd Assay
EP3600221A4 (fr) * 2017-03-22 2021-01-13 Bonti, Inc. Neurotoxines botuliques pour utilisation en thérapie
JP7186228B2 (ja) 2018-02-26 2022-12-08 イプセン バイオファーム リミテッド 非細胞毒性プロテアーゼの注入を案内するための超音波の使用
US11975055B2 (en) 2018-05-21 2024-05-07 Ipsen Biopharm Limited Suppression of bone cancer-induced allodynia
US20220016221A1 (en) 2018-12-05 2022-01-20 Ipsen Biopharm Limited Treatment of symptoms of traumatic brain injury
KR20210097530A (ko) * 2020-01-30 2021-08-09 (주)메디톡스 Snare 복합체의 형성을 저해하는 펩티드, 및 그의 용도
GB202001353D0 (en) 2020-01-31 2020-03-18 Ipsen Biopharm Ltd Treatment of skin conditions
GB202010934D0 (en) 2020-07-15 2020-08-26 Ipsen Biopharm Ltd Controlling operation of a bioreactor vessel
GB202011055D0 (en) 2020-07-17 2020-09-02 Ipsen Bioinnovation Ltd Treatment of post-operative pain
WO2023141417A2 (fr) * 2022-01-18 2023-07-27 Fletcher Paul L Enzymes de clivage de protéines snare à action rapide
WO2024069191A1 (fr) 2022-09-30 2024-04-04 Ipsen Biopharm Limited Neurotoxine clostridiale destinée à être utilisée dans un traitement de la cystite interstitielle

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6776990B2 (en) * 1999-04-08 2004-08-17 Allergan, Inc. Methods and compositions for the treatment of pancreatitis
WO2004080471A1 (fr) * 2003-03-12 2004-09-23 The Holding Company For Biological Products And Vaccines Nouvelle utilisation du venin de scorpion comme substance de traitement du paludisme et de prophylaxie
US20050019346A1 (en) * 2003-05-30 2005-01-27 Boulis Nicholas M. In vivo production of a clostridial neurotoxin light chain peptide
US7456272B2 (en) * 2000-11-29 2008-11-25 Allergan, Inc. Neurotoxins with enhanced target specificity
US20080319167A1 (en) * 1995-04-21 2008-12-25 Keith Alan Foster Clostridial toxin derivatives able to modify peripheral sensory afferent functions

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2793681B1 (fr) 1999-05-18 2001-06-22 Oreal Utilisation d'au moins un inhibiteur d'au moins un canal calcique dans le traitement des rides

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080319167A1 (en) * 1995-04-21 2008-12-25 Keith Alan Foster Clostridial toxin derivatives able to modify peripheral sensory afferent functions
US6776990B2 (en) * 1999-04-08 2004-08-17 Allergan, Inc. Methods and compositions for the treatment of pancreatitis
US7456272B2 (en) * 2000-11-29 2008-11-25 Allergan, Inc. Neurotoxins with enhanced target specificity
WO2004080471A1 (fr) * 2003-03-12 2004-09-23 The Holding Company For Biological Products And Vaccines Nouvelle utilisation du venin de scorpion comme substance de traitement du paludisme et de prophylaxie
US20050019346A1 (en) * 2003-05-30 2005-01-27 Boulis Nicholas M. In vivo production of a clostridial neurotoxin light chain peptide

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FLETCHER, P. L. ET AL.: "Vesicle-associated membrane protein (VAMP) cleavage by a new metalloprotease from the brazilian scorpion tityus serrulatus", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 285, no. 10, 21 December 2009 (2009-12-21), pages 7405 - 7416, XP008151912 *

Also Published As

Publication number Publication date
EP2467477A2 (fr) 2012-06-27
EP2467477B1 (fr) 2014-05-07
US9149666B2 (en) 2015-10-06
CA2770185C (fr) 2019-04-09
US20120225049A1 (en) 2012-09-06
CA2770185A1 (fr) 2011-02-24
WO2011022357A2 (fr) 2011-02-24
EP2467477A4 (fr) 2013-06-19

Similar Documents

Publication Publication Date Title
WO2011022357A3 (fr) Enzymes de clivage de snare à action rapide
WO2012068109A3 (fr) Composés d'hydroxypyrimidine amide utilisés comme inhibiteurs de la protéine déacétylase et leurs procédés d'utilisation
WO2012019168A3 (fr) Acides nucléiques modifiés et leurs procédés d'utilisation
WO2012075040A3 (fr) Arnm pour l'utilisation dans le traitement de maladies génétiques humaines
WO2011041584A3 (fr) Procédés de modulation de l'autophagie par la modulation de produits géniques renforçant l'autophagie
MX2021007268A (es) Formas solidas de acido {[5-(3-clorofenil)-3-hidroxipiridin-2-carb onil]amino}acetico, composiciones, y usos de las mismas.
WO2011053783A3 (fr) Antagonistes et variants ax213 et ax132 pcsk9
WO2009126688A8 (fr) Compositions et procédés nouveaux pour le traitement de maladies de nature immunitaire
WO2011091213A3 (fr) Composés amide inverse en tant qu'inhibiteurs de protéine désacétylase et procédés d'utilisation associés
MX2012011771A (es) Aptameros para beta-ngf y su uso en el tratamiento de enfermedades y trastornos mediados por beta-ngf.
WO2007117438A3 (fr) Méthodes de production d'une protéine fonctionnelle à partir d'un adn présentant une mutation non-sens et traitement des troubles associés
CA2783820C (fr) Variants de proteases
WO2010083207A3 (fr) Inhibiteurs de la protéine kinase c et leurs utilisations
WO2008129023A3 (fr) Compositions d'oligonucléotides pour le traitement de la maladie d' alzheimer
WO2009114475A3 (fr) Compositions comprenant de la pcsk9 humaine et un siarn d’apolipoprotéine b, et procédés d’utilisation de celles-ci
WO2011106541A3 (fr) Méthodes de diagnostic impliquant une perte d'hétérozygosité
WO2009090639A3 (fr) Composés d'arnsi et leurs utilisations
WO2012083302A3 (fr) Compositions et procédés pour le traitement ou la prévention d'une infection par l'adénovirus 36 humain
WO2009002440A3 (fr) Compositions comprenant un arnsi de egfr humain et leurs procédés d'utilisation
WO2013006335A3 (fr) Méthodes et compositions utiles pour traiter des types de peau fitzpatrick iv, v ou vi
WO2011075606A3 (fr) Variants de polypeptide hyperglycosylé et procédés d'utilisation
WO2010003420A3 (fr) Traitement du psoriasis et de maladies apparentées par modulation de miarn
WO2009136997A3 (fr) Inhibiteurs des cathepsines l, b et s humaines
WO2014111876A3 (fr) Modulation de la mitophagie et son utilisation
WO2011021177A3 (fr) Compositions et procédés de pronostic et de traitement du cancer de la prostate

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10810460

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2770185

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2010810460

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 13390674

Country of ref document: US